The warning label placed on all estrogen-based treatments since 2003 was based on an outdated and flawed government-funded study.

Evidence suggests commercial health plans are more likely to delay specialty drug coverage decisions in response to FDA ...

The FDA has approved a label expansion for once-weekly tirzepatide for adults with overweight and obesity, allowing the medication to be used with a pen that is equipped with four doses of the drug, ...

FDA allergen thresholds offer food brands science-based guidance on managing cross-contact risks and using advisory ...

Feb 12 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved labeling changes to six menopause ...

Primary CNS lymphoma is a rare and aggressive cancer with no FDA-approved treatments specific to the disease. While some ...

As one long-running feud over the controversial generic drug carveout known as “skinny” labeling comes to a close, the United States’ top lawyer is urging the Supreme Court to reverse a recent ...

Federal law requires every prescription drug to include a document describing dosing guidelines, contraindications, results ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

The FDA has updated its stance on “no artificial colours” claims, giving manufacturers more flexibility when products exclude ...